ArticleHeart (British Cardiac Society)2002
The economic burden of coronary heart disease in the UK.
Article in Heart (British Cardiac Society), 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The impact of clinical and population strategies on coronary heart disease mortality: an assessment of Rose's big idea.BMC public health · 2022Pooled it
- Economic Burden of Obesity: A Systematic Literature Review.International journal of environmental research and public health · 2017Pooled it
- Estimating productivity costs using the friction cost approach in practice: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2016Pooled it
- Five-year cost-effectiveness analysis of the European Fans in Training (EuroFIT) physical activity intervention for men versus no intervention.The international journal of behavioral nutrition and physical activity · 2020Trial
- A dynamic, modifiable model for estimating cost-effectiveness of smoking cessation interventions in pregnancy: application to an RCT of self-help delivered by text message.Addiction (Abingdon, England) · 2019Trial
- Costs of a community pharmacist-led medicines management service for patients with coronary heart disease in England: healthcare system and patient perspectives.PharmacoEconomics · 2007Trial
- Economic evaluation of the impact of nicorandil in angina (IONA) trial.Heart (British Cardiac Society) · 2006Trial
- Article
- Estimation of economic burden of high salt intake in cardiovascular disease attributed to hypertension in Iran.Cost effectiveness and resource allocation : C/E · 2025Article
- Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran.BMC health services research · 2025Observational
- Real-world evidence study on the impact of SPECT MPI, PET MPI, cCTA and stress echocardiography on downstream healthcare utilisation in patients with coronary artery disease in the US.BMC cardiovascular disorders · 2024Article
- Evaluating the costs of adverse drug events in hospitalized patients: a systematic review.Health economics review · 2024Review
- Characteristics and key differences between patient populations receiving imaging modalities for coronary artery disease diagnosis in the US.BMC cardiovascular disorders · 2023Article
- The burden of chronic diseases and patients' preference for healthcare services among adult patients suffering from chronic diseases in Bangladesh.Health expectations : an international journal of public participation in health care and health policy · 2022Article
- Societal economic burden of hypertension at selected hospitals in southern Ethiopia: a patient-level analysis.BMJ open · 2022Article
- Cost-effectiveness of bariatric surgery and non-surgical weight management programmes for adults with severe obesity: a decision analysis model.International journal of obesity (2005) · 2021Article
- Fat-to-muscle Ratio: A New Indicator for Coronary Artery Disease in Healthy Adults.International journal of medical sciences · 2021Observational
- Economic Burden of Major Diseases in China in 2013.Frontiers in public health · 2021Article
- Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling.BMJ open · 2020Article
- Production losses associated with premature mortality in 28 European Union countries.Journal of global health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the economic burden of coronary heart disease in the UK using both direct and indirect costs. DESIGN AND
settingA prevalence based approach was used to assess coronary heart disease related costs from the societal perspective. PATIENTS: All UK residents in 1999 with coronary heart disease (ICD 9 codes 410-414 and ICD10 codes I20-I25).
main outcome measuresDirect health care costs were estimated from spending on prevention, accident and emergency care, hospital care, rehabilitation, and drug treatment. Direct non-health service costs were estimated from data on informal care. "Friction period" adjusted productivity costs were estimated using the human capital approach from lost earnings attributable to coronary heart disease related mortality and morbidity. The friction period is the period of employees' absence from work before the employer replaces them with other workers. Failure to adjust for this factor would overstate production loss.
resultsCoronary heart disease cost pound 1.73 billion to the UK health care system in 1999: pound 2.42 billion in informal care and pound 2.91 billion in friction period adjusted productivity loss; 24.1% of production losses were attributable to mortality and 75.9% to morbidity. The total annual cost of all coronary heart disease related burdens was pound 7.06 billion, the highest of all diseases in the UK for which comparable analyses have been done.
conclusionsCoronary heart disease is a leading public health problem in the UK in terms of the economic burden from disease. Cost estimates would be substantially understated if informal care/productivity costs were excluded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.